MOH — Molina Healthcare Inc
Is MOH overbought or oversold? Here is the current MarketMoodz read.
Molina Healthcare Inc (MOH) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Healthcare Plans) last closed at $233.09. The rating moved from Neutral to Overbought on November 14, 2026.
- Public ratingOverbought (as of November 17, 2026)
- Last close$233.09
- Last changeMoved from Neutral to Overbought on November 14, 2026
- SectorHealthcare
- IndustryHealthcare Plans
See all overbought Healthcare stocks →
AI analysis
Molina Healthcare Inc (MOH) benefits from a defensible mix of Medicaid and growing Medicare Advantage membership that produces stable, government-backed cash flows. Recent sector dynamics (MA benefit expansion and defensive flows into healthcare) create a constructive near-term backdrop, while earnings and enrollment updates represent the primary catalysts. Main constraints include reimbursement/regulatory risk, margin sensitivity to benefit expansion and state-level compliance exposures. Overall, the company’s cash generation and enrollment footprint support upside over the next month, balanced against medium-term policy and competitive risks.
Key factors
- Material exposure to Medicaid and expanding Medicare Advantage markets provides stable, government-backed revenue streams
- Medicare Advantage benefit expansion trends can increase membership and per-member revenue if Molina captures enrollment gains
- Defensive flows into healthcare and large-cap pharma strength support sector interest and reduce downside volatility
- Consistent cash flow generation and historically disciplined capital allocation support balance sheet flexibility
- Diversified product mix (Medicaid, Medicare, Marketplace) provides countercyclical demand during economic stress
- Near-term catalysts: earnings cadence, enrollment updates, and clarity on policy/monetary signals that reduce uncertainty
Risks
- Regulatory and reimbursement risk from federal/state Medicaid policy changes or tighter MA reimbursement pressure
- Political and antitrust scrutiny of the broader healthcare industry that could affect partnerships, PBMs, or integrated models
- Margin pressure from aggressive $0-premium MA plans, richer benefits or higher medical cost trends
- State-level contract, compliance or audit risks that can lead to material reserve or payment disruptions
- Competitive pressure from larger national payors and vertically integrated players expanding into Medicaid/MA
- Macroeconomic shocks or spikes in interest rates that reduce investor risk appetite for healthcare equities
See today's live rating, score and targets
Members see the live hourly rating for MOH — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.